VCNX

Vaccinex, Inc.

0.90 USD

Last updated Nov 30, 03:55 UTC

Yesterday HIGH

$0.87

Yesterday LOW

$0.77

52w HIGH

$12.35

52w LOW

$0.77

EPS

-1.09

PE

-0.83

Next Earnings

Apr 1, 2024

Overview News Insider Transactions Government Trades

Vaccinex, Inc. stock is down -6.16% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 November’s closed higher than October.

Vaccinex, Inc. engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

vaccinex.com

Benzinga Insights

Fri Sep 29, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
Lisa Levin

Fri Sep 29, 2023

Why Glimpse Group Shares Are Trading Lower By Around 41%; Here Are 20 Stocks Moving Premarket

Gainers RVL Pharmaceuticals plc (NASDAQ: RVLP) shares rose 181.8% to $0.2201 in pre-market trading.
Benzinga Newsdesk

Fri Sep 29, 2023

Vaccinex Prices $9.6M Public Offering Of 9.6M Common Shares And Warrants At $1/Share

Vaccinex has entered into securities purchase agreements with healthcare focused institutional investors along-side significant participation from an entity affiliated with the Chairman of the Company's Board of
Benzinga Insights

Thu Sep 28, 2023

Stocks That Hit 52-Week Lows On Thursday

During Thursday's session, 406 companies made new 52-week lows.
Benzinga Newsdesk

Thu Sep 28, 2023

Vaccinex's Next Generation ActivMAb Technology Published In mAbs, A Leading Biotech Journal, And Validated In OmniAb Proof-Of-Concept Collaboration

Application is based on proprietary poxvirus system that enables Hard-to-Drug Complex Proteins to be expressed at high levels in their "native conformation" so as to efficiently induce and select specific
Benzinga Insights

Tue Sep 26, 2023

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 386 stocks made new 52-week lows.
Benzinga Newsdesk

Tue Sep 26, 2023

Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development Of Pepinemab For The Treatment Of Neurodegenerative Diseases And Cancer

"Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease" will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer's Disease Conference to be held
Lisa Levin

Mon Sep 25, 2023

Thor Industries, AutoNation And 3 Stocks To Watch Heading Into Monday

With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Benzinga Newsdesk

Fri Sep 22, 2023

Vaccinex, Inc. Announces 1-For-15 Reverse Stock Split

Vaccinex, Inc., (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will
Benzinga Insights

Thu Sep 21, 2023

Stocks That Hit 52-Week Lows On Thursday

During the session on Thursday, 461 stocks hit new 52-week lows.